Finance

Lists
Outlook: 37.5% bullish·0.0% bearish
Go to analysis
WST:NYSE
West Pharmaceutical Services Inc
$366.48
-1.65%
(-6.16) 1D
$366.48
0.00% (0.00)
After hours
Closed: Oct 7, 4:00:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for WST...
Open
$371.66
High
$374.79
Low
$365.34
Mkt. cap
25.79B
Avg. vol.
573.98K
Volume
437.99K
Dividend
0.24%
Quarterly dividend
$0.22
Ex-dividend date
Jul 29, 2026
P/E ratio
46.85
52-wk high
$386.00
52-wk low
$223.83
EPS
$7.82
Beta
1.13
Shares outstanding
70.38M
No. of employees
11K
Open
$371.66
High
$374.79
Low
$365.34
Mkt. cap
25.79B
Avg. vol.
573.98K
Volume
437.99K
Dividend
0.24%
Quarterly dividend
$0.22
Ex-dividend date
Jul 29, 2026
P/E ratio
46.85
52-wk high
$386.00
52-wk low
$223.83
EPS
$7.82
Beta
1.13
Shares outstanding
70.38M
No. of employees
11K
News stories
From web sources and news partners
Profile
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin. Wikipedia
About West Pharmaceutical Services Inc
CEOEric M. Green
Employees10.8K
Founded1923
HeadquartersWest Whiteland Township, Pennsylvania, United States
SectorHealth care
Websitewestpharma.com
Analyst ratings
Based on 9 analysts giving stock ratings to WST in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for WST in the last 3 months.
Highest
Current $366.48
$447.00 (+21.97%)
Average
$419.88 (+14.57%)
Lowest
$400.00 (+9.15%)
Analyst
Recommendation
Action
Price target
Projected
Date
Luke Sergott
Barclays
Buy
Maintained
$440.00
+20.1%
10/07/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Upgraded
$400.00
+9.1%
09/22/2026
Unknown Analyst
UBS
Buy
Maintained
$415.00
+13.2%
09/09/2026
Doug Schenkel
UBS
Buy
Maintained
$415.00
+13.2%
09/09/2026
Joanne Wuensch
Citi
Buy
Maintained
$412.00
+12.4%
08/03/2026
Daniel Markowitz CFA
Evercore ISI
Buy
Maintained
$425.00
+16%
07/27/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
$410.00
+11.9%
07/24/2026
Brendan Smith
TD Cowen
Buy
Reiterated
$410.00
+11.9%
07/23/2026
Matt Larew
William Blair
Buy
Maintained
-
-
07/23/2026
Curtis Moiles
Exane BNP Paribas
Buy
Initiated
$447.00
+22%
07/13/2026
Paul Knight
KeyBanc
Buy
Maintained
$390.00
+6.4%
07/02/2026
Michael Polark
Wolfe Research
Buy
Reiterated
$375.00
+2.3%
06/01/2026
Patrick B Donnelly
Citi
Buy
Maintained
$400.00
+9.1%
04/24/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
-
-
04/23/2026
Dan Leonard
UBS
Buy
Maintained
$340.00
-7.2%
02/13/2026
Justin Bowers
Deutsche Bank
Buy
Maintained
$315.00
-14%
02/13/2026
David Windley
Jefferies
Buy
Maintained
$295.00
-19.5%
02/10/2026
Nico Chen
DBS
Buy
Maintained
$320.00
-12.7%
01/28/2026
Last report
Jul 23, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$2.37 / $2.08
+13.86%beat
Revenue / Est. (USD)
872.30M / 839.98M
+3.85%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
804.60M
805.00M
844.90M
872.30M
Cost of goods sold
510.30M
501.10M
548.50M
543.10M
Cost of revenue
510.30M
501.10M
548.50M
543.10M
Research and development expenses
17.10M
21.80M
15.80M
19.70M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
101.10M
107.50M
99.50M
112.00M
Operating expense
118.50M
129.70M
113.10M
133.20M
Total operating expenses
628.80M
630.80M
661.60M
676.30M
Operating income
175.80M
174.20M
183.30M
196.00M
Other non operating income
-200.00K
600.00K
-200.00K
-200.00K
EBT including unusual items
174.00M
165.40M
183.50M
186.20M
EBT excluding unusual items
179.50M
181.20M
188.60M
201.20M
Income tax expense
34.00M
33.30M
44.70M
32.20M
Effective tax rate
19.54%
20.13%
24.36%
17.29%
Other operating expenses
300.00K
400.00K
-2.20M
1.50M
Net income
140.00M
132.10M
138.80M
154.00M
Net profit margin
17.40%
16.41%
16.43%
17.65%
Earnings per share
1.96
2.04
2.13
2.37
Interest and investment income
4.70M
5.30M
5.10M
3.80M
Interest expense
-200.00K
-
-1.90M
-2.60M
Net interest expenses
4.50M
5.30M
3.20M
1.20M
Depreciation and amortization charges
-
-
-
-
EBITDA
218.80M
221.20M
228.50M
242.20M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps